Replies to post #1723 on Revance Therapeutics Inc (RVNC)

[DewDiligence]

EOLS PR_re_21-month_Jeuveau_ban_from_US_market:

https://finance.yahoo.com/news/evolus-provides-united-states-international-224500084.html

According to the above PR, the ITC reversed its preliminary ruling that EOLS’ Korean supplier, Daewoong, stole Medytox’s trade secrets, but the ITC upheld its preliminary ruling that EOLS is in violation of US tariff law. Hence, the ban on Jeuveau sales runs for 21 months rather than (the preliminary ITC remedy of) ten years.

For RVNC, this ruling doesn’t mean a whole lot, but it’s modestly helpful to RVNC that Jeuveau won’t be on the US market when Daxi is launched in 2021.